咨询热线:4006-400-850

收藏
当前位置:首页 > 莫纳生物 > 细胞及转染
细胞及转染 联系我们
< >
DNA-In® Transfection Reagent

DNA-In® is the newest generation transfection product developed by the lead members of the scientific team that invented the Lipofectamine® and Lipofectamine® 2000. DNA-In® is a novel cationic tran

  • 产品介绍
  • 规格参数
  • 售后服务

DNA-In® Transfection Reagent

A Universal Transfection Reagent for DNA Delivery

DNA-In®  is the newest generation transfection product developed by the lead members of the scientific team that invented the Lipofectamine® and Lipofectamine® 2000.  DNA-In®  is a novel cationic transfection reagent which balances high transfection and expression levels with low toxicity.  DNA-In®  works on a very broad range of adherent cells including most passaged cell lines and many primary cells.

  • Product sheet

  • Features

  • Fast, simple, easy-to-follow protocol

  • One-step process: simply add DNA-In®  Reagent to diluted DNA, incubate 10 minutes, and add to pre-plated cells

  • Minimal toxicity - no need to replace medium after transfection

DNA-In®  Transfection Reagent  "Quick-Start Protocol"


Superior Transfection Efficiency


During its development and validation process, DNA-In®  Reagent underwent extensive testing in many primary and cultured cells. In a head-to-head comparison study, DNA-In® consistently outperformed the Lipofectamine® 2000 transfection reagent.


Cells were transfected with a plasmid, containing EmeraldGFP behind an EF1α promoter, with either DNA-In®  or Lipofectamine®2000, at several different lipid:DNA ratios and examined ~44 hours post-transfection. Representative images of the best conditions for each transfection reagent are shown.

Low Cell Toxicity 

DNA-In®  has a significantly lower cell toxicity compared to traditional transfection reagents such as Lipofectamine®  and Lipofectamine®  2000.  In the many cell lines tested, DNA-In® shows a broad range of effective dosage while maintaining minimal cell toxicity.  This low cell toxicity allows a larger dosage and time window for optimized transfection results.

The following charts show side-by-side comparisons of DNA-In®  and Lipofectamine® 2000 (LF2K) in commonly used cell lines and primary cells:

In 293 cells, DNA-In®  maintains high cell viability throughout the tested dosage range, while LF2K has a significant cell toxicity issue when used in dosages over 3µl.

In A549 cells, DNA-In®  has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.

In human fibroblast cells, DNA-In®  has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.

In HeLa cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.


In HepG2 cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.

In MCF7 cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K transfection efficiency is lower and is toxic when used in dosages higher than 2µl.


版权所有:默瑞(上海)生物科技有限公司   

技术支持:易动力网络